nirmacom tablets

Product Description

Pharmaceutical company Hetero on December 26 saidit has received World Health Organization Prequalification of MedicinesProgramme (WHO PQ) approval for its generic version of Covid-19 oral antiviraltreatment candidate nirmatrelvir.

Nirmatrelvir,which originated in Pfizer laboratories, is co-packaged with ritonavir tabletsas Pfizers Covid 19 oral antiviral drug Paxlovid. This is the firstprequalification for a generic version of Paxlovid, Hetero said.

Thecombi pack launched by Hetero as Nirmacom will contain nirmatrelvir 150 mg (twotablets) and ritonavir 100 mg (one tablet). A prescription only drug that thecompany said be initiated as soon as possible after diagnosis of Covid-19 andwithin five days of symptom onset, Nirmacom is be manufactured at Heterosfacilities in the country.

WHOhad made a strong recommendation for nirmatrelvir and ritonavir for mild andmoderate Covid-19 patients at highest risk of hospital admission, such asunvaccinated, aged or immunosuppressed patients, Hetero said in a release.